Analysts Impressed As Novo Nordisk’s PIONEER 6 Trial Confirms Safety Profile Of Oral Semaglutide
Oral semaglutide hit its main endpoint by demonstrating cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in the PIONEER 6 trial.
You may also be interested in...
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.